Stocktoria

Jasper Therapeutics, Inc. JSPR

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-11-20

Jasper Therapeutics, Inc. statistics & valuation

Market cap$9.6M
P / B2.3×
Return on capital-371.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-44.10% -104.70% -82.20% -115.60% -1826.10% 202020212022202320242025
Shares outstanding
2.8M 37.9M 3.8M 11.2M 15.0M 28.0M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-135.60% -32.70% -77.90% -67.90% -89.20% -211.90% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$2.69 -$10.33 -$6.18 -$4.89 -$3.95 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-211.9%-89.2%-67.9%-77.9%-32.7%-135.6%
Return on equity-1826.1%-115.6%-82.2%-104.7%-44.1%90.1%
Current ratio2.624.987.195.9110.955.16

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.